Reference

1 Benetos, A., Gautier, S., Ricard, S., et al. (1996) Influence of angiotensin-con-verting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 94, 698-703.

2 Chung, O. and Unger, T. (1999) Angiotensin II receptor blockade and end-organ protection. Am. J. Hypertens. 12, S150-S156.

3 Kurland, L., Melhus, H., Karlsson, J., et al. (2002) Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish

Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J. Hypertens. 20, 657-663.

4 Unger, T. (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am. J. Cardiol. 89, 3A-9A.

5 De Paepe, B., Verstraeten, V. M., De Potter, C. R., et al. (2002) Increased angio-tensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem. Cell Biol. 111, 13-19.

6 De Paepe, B., Verstraeten, V. L., De Potter, C. R., et al. (2001) Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem. Cell. Biol. 116, 247-254.

7 Schmieder, R. E., Erdmann, J., Delles, C., et al. (2001) Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J. Am. Coll. Cardiol. 31, 175-182.

8 Ichihara, S., Senbonmatsu, T., Price, E., Jr., et al. (2001) Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104, 346-351.

9 Bloem, L. J., Foroud, T. M., Ambrosius, W. T., et al. (1997) Association of the angiotensinogen gene to serum angiotensinogen in blacks and whites. Hypertension 29, 1078-1082.

10 Kim, H. S., Krege, J. H., Kluckman, K. D., et al. (1995) Genetic control of blood pressure and the angiotensinogen locus. Proc. Natl. Acad. Sci. USA 92, 2735-2739.

11 Walker, W. G., Whelton, P. K., Saito, H., et al. (1979) Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1, 287-291.

12. Fukamizu, A., Sugimura, K., Takimoto, E., et al. (1993) Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J. Biol. Chem. 268, 11,617-11,621.

13 Davisson, R. L., Ding, Y., Stec, D. E., et al. (1999) Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice. Physiol. Genomics 1, 3-9.

14 Merrill, D. C., Thompson, M. W., Carney, C. L., et al. (1996) Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J. Clin. Invest. 91, 1047-1055.

15 Morimoto, S., Cassell, M. D., Beltz, T. G., et al. (2001) Elevated blood pressure in transgenic mice with brain-specific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter. Circ. Res. 89, 365-372.

16 Ohkubo, H., Kawakami, H., Kakehi, H., et al. (1990) Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. PNAS 81, 5153-5157.

17 Stec, D. E., Keen, H. L., and Sigmund, C. D. (2002) Lower blood pressure in floxed angiotensinogen mice after adenoviral delivery of cre-recombinase. Hypertension 39, 629-633.

18 Morishita, R., Higaki, J., Miyazaki, M., et al. (1992) Possible role of the vascular renin-angiotensin system in hypertension and vascular hypertrophy. Hypertension 19, II62-II67.

19 Morton, J. J. and Wallace, E. C. (1983) The importance of the renin-angiotensin system in the development and maintenance of hypertension in the two-kidney one-clip hypertensive rat. Clin. Sci. (Lond.) 64, 359-370.

20 Phillips, M. I. and Kimura, B. K. (1986) Levels of brain angiotensin in the spontaneously hypertensive rat and treatment with ramiprilat. J. Hypertens. Suppl. 4, S391-S394.

21 Phillips, M. I. and Kimura, B. (1988) Brain angiotensin in the developing spontaneously hypertensive rat. J. Hypertens. 6, 607-612.

22. Navar, L. G., Von Thun, A. M., Zou, L., et al. (1995) Enhancement of intrarenal angiotensin II levels in 2 kidney 1 clip and angiotensin II induced hypertension. Blood Pressure Suppl. 2, 88-92.

23 Brown, L., Passmore, M., Duce, B., et al. (1997) Angiotensin receptors in cardiac and renal hypertrophy in rats. J. Mol. Cell. Cardiol. 29, 2925-2929.

24 Gutkind, J. S., Kurihara, M., and Saavedra, J. M. (1988) Increased angiotensin II receptors in brain nuclei of DOCA-salt hypertensive rats. Am. J. Physiol. 255, H646-H650.

25 Atwood, L. D., Kammerer, C. M., Samollow, P. B., et al. (1997) Linkage of essential hypertension to the angiotensinogen locus in Mexican Americans. Hypertension 30, 326-330.

26 Corvol, P. and Jeunemaitre, X. (1997) Molecular genetics of human hypertension: role of angiotensinogen. Endocr. Rev. 18, 662-677.

27. Jain, S., Tang, X., Chittampalli, S. N., et al. (2002) Angiotensinogen gene polymorphism at -217 affects basal promoter activity and is associated with hypertension in African-Americans. J. Biol. Chem. 277, 36,889-36,896.

28 Niu, T., Xu, X., Rogus, J., et al. (1998) Angiotensinogen gene and hypertension in Chinese. J. Clin. Invest. 101, 188-194.

29. Agerholm-Larsen, B., Nordestgaard, B. G., and Tybjarg-Hansen, A. (2000) ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscl. Thrombo. Vasc. Biol. 20, 484-492.

30. O'Donnell, C. J., Lindpaintner, K., Larson, M. G., et al. (1998) Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 97, 1766-1772.

31 Bonnardeaux, A., Davies, E., Jeunemaitre, X., et al. (1994) Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24, 63-69.

32 Phillips, M. I. and Schmidt-Ott, K. M. (1999) The discovery of renin 100 years ago. News Physiol. Sci. 14, 271-274.

33 Phillips, M. I. (2001) Gene therapy for hypertension: sense and antisense strategies. Expert. Opin. Biol. Ther. 1, 655-662.

34 Phillips, M. I. (2001) Gene therapy for hypertension: the preclinical data. Hypertension 38, 543-548.

35 Phillips, M. I. (2000) Somatic gene therapy for hypertension. Braz. J. Med. Biol. Res. 33, 715-721.

36. Kaplan, N. M. (1998) Clinical Hypertension. Williams & Wilkins, Baltimore, 1998.

37 Hodgson, T. A. and Cai, L. (2001) Medical care expenditures for hypertension, its complications, and its comorbidities. Med. Care 39, 599-615.

38. Kagiyama, S., Kagiyama, T., and Phillips, M. I. (2001) Antisense oligonucleotides strategy in the treatment of hypertension. Curr. Opin. Mol. Ther. 3, 258-264.

39 Phillips, M. I., Wielbo, D., and Gyurko, R. (1994) Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. Kidney Int. 46, 1554-1556.

40 Dzau, V. J., Mann, M. J., Morishita, R., et al. (1996) Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc. Natl. Acad. Sci. USA 93, 11,42111,425.

41 Fillion, P., Desjardins, A., Sayasith, K., et al. (2001) Encapsulation of DNA in negatively charged liposomes and inhibition of bacterial gene expression with fluid liposome-encapsulated antisense oligonucleotides. Biochim. Biophys. Acta 1515, 44-54.

42 Hughes, J. A., Bennett, C. F., Cook, P. D., et al. (1994) Lipid membrane permeability of 2'-modified derivatives of phosphorothioate oligonucleotides. J. Pharm. Sci. 83, 597-600.

43 Zhang, Y. C., Bui, J. D., Shen, L., et al. (2000) Antisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation 101, 682-688.

44 Zhang, Y. M., Rusckowski, M., Liu, N., et al. (2001) Cationic liposomes enhance cellular/nuclear localization of 99mTc-antisense oligonucleotides in target tumor cells. Cancer Biother. Radiopharm. 16, 411-419.

45 Morishita, R., Gibbons, G. H., Ellison, K. E., et al. (1993) Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA 90, 8474-8478.

46 Makino, N., Sugano, M., Ohtsuka, S., et al. (1999) Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats. Cardiovasc. Res. 44, 543-548.

47. Clare, Z. Y., Kimura, B., Shen, L., et al. (2000) New beta-blocker: prolonged reduction in high blood pressure with beta(1) antisense oligodeoxynucleotides. Hypertension 35, 219-224.

48 Li, B., Hughes, J. A., and Phillips, M. I. (1997) Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Neurochem. Int. 31, 393-403.

49 Mohuczy, D. and Phillips, M. I. (2000) Designing antisense to inhibit the renin-angiotensin system. Mol. Cell. Biochem. 212, 145-153.

50 Merdan, T., Kopecek, J., and Kissel, T. (2002) Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 54, 715-758.

51 Tang, X., Mohuczy, D., Zhang, Y. C., et al. (1999) Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension. Am. J. Physiol. 277, H2392-H2399.

52 Zhang, Y., Jeong, L. H., Boado, R. J., et al. (2002) Receptor-mediated delivery of an antisense gene to human brain cancer cells. J. Gene Med. 4, 183-194.

53 Kimura, B., Mohuczy, D., Tang, X., et al. (2001) Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense. Hypertension 37, 376-380.

54 Phillips, M. I., Mohuczy-Dominiak, D., Coffey, M., et al. (1997) Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense. Hypertension 29, 374-380.

55 Lu, D., Raizada, M. K., Iyer, S., et al. (1997) Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension 30, 363-370.

56 Metcalfe, B. L., Raizada, M., and Katovich, M. J. (2002) Genetic targeting of the renin-angiotensin system for long-term control of hypertension. Curr. Hypertens. Rep. 4, 25-31.

57 Wang, H., Lu, D., Reaves, P. Y., et al. (2000) Retrovirally mediated delivery of angiotensin II type 1 receptor antisense in vitro and in vivo. Methods Enzymol. 314, 581-590.

58 Hauswirth, W. W. and McInnes, R. R. (1998) Retinal gene therapy 1998: summary of a workshop. Mol. Vis. 4, 11.

59 Sinnayah, P., Lindley, T. E., Staber, P. D., et al. (2002) Selective gene transfer to key cardiovascular regions of the brain: comparison of two viral vector systems. Hypertension 39, 603-608.

60 Gyurko, R., Wielbo, D., and Phillips, M. I. (1993) Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49, 167-174.

61 Ambuhl, P., Gyurko, R., and Phillips, M. I. (1995) A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin AT1 receptor. Regul. Pept. 59, 171-182.

62 Gyurko, R., Tran, D., and Phillips, M. I. (1997) Time course of inhibition of hypertension by antisense oligonucleotides targeted to AT1 angiotensin receptor mRNA in spontaneously hypertensive rats. Am. J. Hypertens. 10, 56S-62S.

63 Piegari, E., Galderisi, U., Berrino, L., et al. (2000) In vivo effects of partial phosphorothioated AT1 receptor antisense oligonucleotides in spontaneously hypertensive and normotensive rats. Life Sci. 66, 2091-2099.

64 Kagiyama, S., Varela, A., Phillips, M. I., et al. (2001) Antisense inhibition of brain renin-angiotensin system decreased blood pressure in chronic 2-kidney, 1 clip hypertensive rats. Hypertension 37, 371-375.

65 Peng, J. F., Kimura, B., Fregly, M. J., et al. (1998) Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and ATI-receptor mRNA in brain and blood. Hypertension 31, 1317-1323.

66 Meng, H., Wielbo, D., Gyurko, R., et al. (1994) Antisense oligonucleotide to AT1 receptor mRNA inhibits central angiotensin induced thirst and vasopressin. Regul. Pept. 54, 543-551.

67 Sakai, R. R., Ma, L. Y., He, P. F., et al. (1995) Intracerebroventricular administration of angiotensin type 1 (AT1) receptor antisense oligonucleotides attenuate thirst in the rat. Regul. Pept. 59, 183-192.

68 Galli, S. M. and Phillips, M. I. (2001) Angiotensin II AT(1A) receptor antisense lowers blood pressure in acute 2-kidney, 1-clip hypertension. Hypertension 38, 674-678.

69 Yang, B., Li, D., Phillips, M. I., et al. (1998) Myocardial angiotensin II receptor expression and ischemia-reperfusion injury. Vasc. Med. 3,121-130.

70 Iyer, S. N., Lu, D., Katovich, M. J., et al. (1996) Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense. Proc. Natl. Acad. Sci. USA 93, 9960-9965.

71 Pachori, A. S., Numan, M. T., Ferrario, C. M., et al. (2002) Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension 39, 969-975.

72 Wielbo, D., Sernia, C., Gyurko, R., et al. (1995) Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 25, 314-319.

73 Kagiyama, S., Tsuchihashi, T., Abe, I., et al. (1999) Antisense inhibition of angiotensinogen attenuates vasopressin release in the paraventricular hypotha-lamic nucleus of spontaneously hypertensive rats. Brain Res. 829, 120-124.

74 Sinnayah, P., Kachab, E., Haralambidis, J., et al. (1997) Effects of angiotensinogen antisense oligonucleotides on fluid intake in response to different dipsogenic stimuli in the rat. Brain Res. Mol. Brain Res. 50, 43-50.

75 Sinnayah, P., McKinley, M. J., and Coghlan, J. P. (1997) Angiotensinogen antisense oligonucleotides and fluid intake. Clin. Exp. Hypertens. 19, 993-1007.

76 Wielbo, D., Simon, A., Phillips, M. I., et al. (1996) Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension 28, 147-151.

77 Makino, N., Sugano, M., Ohtsuka, S., et al. (1998) Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 31, 1166-1170.

78 Sugano, M., Tsuchida, K., Sawada, S., et al. (2000) Reduction of plasma angio-tensin II to normal levels by antisense oligodeoxynucleotides against liver angiotensinogen cannot completely attenuate vascular remodeling in spontaneously hypertensive rats. J. Hypertens. 18, 725-731.

79 Tomita, N., Morishita, R., Higaki, J., et al. (1995) Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 26, 131-136.

80 Morishita, R., Gibbons, G. H., Tomita, N., et al. (2000) Antisense oligodeoxynucle-otide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: evidence for tissue angiotensin-converting enzyme function. Arterioscl. Thromb. Vasc. Biol. 20, 915-922.

81 Chen, H., Mohuczy, D., Li, D., et al. (2001) Protection against ischemia/ reperfusion injury and myocardial dysfunction by antisense-oligodeoxynucleotide directed at angiotensin-converting enzyme mRNA. Gene Ther. 8, 804-810.

82. Phillips, M. I. and Kimura, B. (1999) Central nervous system and angiotensin in the development of hypertension. In: Development of the Hypertensive Pheno-type: Basic and Clinical Studies. (McCarty, R., Blizard, D. A., Chevalier, R. L., eds.), Elsevier Science B.V., pp. 383-411.

83 Nakamura, S., Moriguchi, A., Morishita, R., et al. (1999) Activation of the brain angiotensin system by in vivo human angiotensin-converting enzyme gene transfer in rats. Hypertension 34, 302-308.

84 Kubo, T., Ikezawa, A., Kambe, T., et al. (2001) Renin antisense injected intraven-tricularly decreases blood pressure in spontaneously hypertensive rats. Brain Res. Bull. 56, 23-28.

85 Moore, A. F., Heiderstadt, N. T., Huang, E., et al. (2001) Selective inhibition of the renal angiotensin type 2 receptor increases blood pressure in conscious rats. Hypertension 37, 1285-1291.

86 Orr, R. M. (2001) Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/ CIBA vision. Curr. Opin. Mol. Ther. 3, 288-294.

87 de Smet, M. D., Meenken, C. J., and van den Horn, G. J. (1999) Fomivirsen—a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflamm. 7, 189-198.

88 Acland, G. M., Aguirre, G. D., Ray, J., et al. (2001) Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92-95.

89 Freytag, S. O., Khil, M., Stricker, H., et al. (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62, 4968-4976.

90 Reid, T., Galanis, E., Abbruzzese, J., et al. (2001) Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 8, 1618-1626.

91 Harvey, B. G., Maroni, J., O'Donoghue, K. A., et al. (2002) Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene Ther. 13, 15-63.

92 The, B. S., Aguilar-Cordova, E., Kernen, K., et al. (2001) Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer—a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 51, 605-613.

93 Lamont, J. P., Nemunaitis, J., Kuhn, J. A., et al. (2000) A prospective phase II trial of 0NYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann. Surg. Oncol. 7, 588-592.

94 Nishii, T., Moriguchi, A., Morishita, R., et al. (1999) Angiotensinogen gene-activating elements regulate blood pressure in the brain. Circ. Res. 85, 257-263.

95 Katovich, M. J., Reaves, P. Y., Francis, S. C., et al. (2001) Gene therapy attenuates the elevated blood pressure and glucose intolerance in an insulin-resistant model of hypertension. J. Hypertens. 19, 1553-1558.

96. Morishita, R., Higaki, J., Tomita, N., et al. (1996) Role of transcriptional ciselements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation. Hypertension 27, 502-507.

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook


Post a comment